Yemaachi is developing the most diverse cancer knowledge base in the world and advancing clinical research across the African continent. This research includes work to identify novel biomarkers for early detection of cancer among African populations and develop novel diagnostic tools based on these markers, as well as identify novel therapeutic targets that are extensible to broad populations.
The Yemaachi Cancer Knowledge Base is a first-of-its-kind bio-database that includes clinical and molecular data from across the African continent – the world’s most genetically diverse human population. We harness our unmatched network of clinical partners globally and our deep expertise in molecular biology, immunogenomics, and machine learning. Our goal is to develop the next generation of cancer drugs and diagnostic tools that are effective in diverse populations.
Contribution of genetic variation to the metabolism of drugs in tumour and pericarcinomatous liver fractions from hepatocellular carcinoma donors
The ALIVE Study leverages the pharmacology expertise at H3D and the genomics and computational biology capacity at Yemaachi to understand how drug metabolism varies across the continent, with the aim of better optimizing treatment regimens for African populations.
Liquid Biopsy for Detection of Actionable Genomic Mutations in Women of African Descent with Advanced Breast Cancer
The AMBER Study is a prospective, observational trial exploring the utility of a cfDNA liquid biopsy assay to identify actionable genetic mutations in metastatic breast cancer patients in Ghana.
Genetic Characterisation of Cancers in Africa
This study aims to understand genetic factors mediating selected solid tumour cancers in Africans. Due to considerable differences in genetic diversity between African and Caucasian populations, largely Eurocentric cancer research findings are not fully representative of Africans. This study is in collaboration with researchers in Senegal, Nigeria, Côte d’Ivoire, Tunisia, Kenya and Uganda.
Investigating the immune kinetics of COVID-19 vaccine responses between European and African populations
The purpose of this study is to understand immune response to the COVID-19 vaccine. This research study is led by Yemaachi Biotech Ltd, in partnership with Ghana Health Service, West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), Francis Crick Institute, and Bill & Melinda Gates Foundation.
Sequencing for Covid Mitigation in Ghana
A partnership between Yemaachi Biotech Ltd and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) to provide critical real-time information on the evolution of the SARS-CoV-2 virus across Ghana.
Paediatric Oncology in Ghana Research Sites
The aim of this study is to improve childhood cancer survival in Ghana by advancing research into diagnosis, treatment, follow up and determinants of outcomes of 6 cancers prioritised by the Global Initiative for Childhood Cancers (GICC) – Acute Lymphoblastic Leukaemia (ALL), Burkitt Lymphoma, Hodgkin Lymphoma, Wilms Tumour, Retinoblastoma, and low-grade gliomas.
Interested in learning more about Yemaachi clinical research opportunities or the Yemaachi Cancer Knowledge Base? Are you a researcher who wants to contribute or work with de-identified data?
|This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
|The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
|This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
|This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
|This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".